Acceptability of ‘as needed’ biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljae068 ↗Kurz gefasst
Mixed-Methods-Studie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von David Gleeson und 11 weiteren Autor:innen. Beteiligte Einrichtung: St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. Hauptthemen laut MEDLINE: Psoriasis, Attitude of Health Personnel. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Doctoral Training Fellow, NIHR Advanced Fellowship.
Abstract (Originalsprache)
Background
Biologic therapies have led to increasing numbers of patients with psoriasis who have clear or nearly clear skin. It is current practice to continue biologic therapy indefinitely in these patients, which contributes to a substantial long-term drug and healthcare burden. ‘As needed’ biologic therapy in psoriasis may address this; however, our understanding of patient and clinician perceptions of this strategy is limited.
Objectives
The aim of this mixed-methods study was to gain insight into the perspectives of both patients and clinicians regarding the acceptability of an ‘as needed’ approach to biologic therapy in psoriasis, including potential barriers and enablers to implementation in routine care.
Methods
We first conducted UK-wide online scoping surveys of patients with psoriasis and dermatology clinicians to explore their views on ‘as needed’ biologic therapy. Using topic guides informed by these survey findings, we then carried out qualitative focus groups with patients and clinicians. Themes were identified using reflexive thematic analysis.
Results
Of 67 patients and 27 clinicians completing the scoping surveys, 67% (43 of 64 patients) and 78% (21 of 27 clinicians) supported the use of ‘as needed’ biologic therapy, respectively. Respondents highlighted advantages such as a reduction in healthcare burden and greater ownership of care. Challenges included logistics of ‘as needed’ drug provision and potential risks of disease flare and drug immunogenicity. Focus groups comprised 15 patients with psoriasis [9 female patients (60%), average disease duration 32 years (range 9–64)] and 9 dermatology clinicians [8 female clinicians (89%), average dermatology experience 20 years (range 8–33)]. Both patients and clinicians felt that an ‘as needed’ treatment approach will deliver a reduction in treatment burden and present an opportunity for patient-led ownership of care. Both groups highlighted the importance of ensuring ongoing access to medication and discussing the potential impact of psoriasis recurrence. Patient preferences were influenced by their lived experiences, particularly previous difficulties with medication delivery logistics and establishing disease control. Clinician perspectives were informed by personal experience of their patients adapting their own dosing schedules. Clinicians highlighted the importance of targeted patient selection for an ‘as needed’ approach, ongoing disease monitoring, and prompt reaccess to medications upon psoriasis recurrence.
Conclusions
These data indicate that ‘as needed’ biologic therapy in psoriasis is acceptable for both patients and clinicians. Formal assessment of clinical effectiveness and cost-effectiveness is warranted to enable the real-world potential of this approach to be realized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Psoriasis Association, Northampton, Northamptonshire, UK.
- Centre for Adherence Research and Education, Faculty of Life Sciences & Medicine, King's College London, London, UK.
- Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
ORCID-Profile: Sam Norton
Förderung
- National Institute for Health and Care Research
- Doctoral Training Fellow
- NIHR Advanced Fellowship
- Psoriasis Association
Zitieren
APA
Gleeson, D., Naveed, M., Moorhead, L., McAteer, H., Sewell, G., McGuire, A., Weinman, J., Barker, J. N. W. N., Norton, S., Chapman, S. C. E., Smith, C. H., & Mahil, S. K. (2024). Acceptability of ‘as needed’ biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae068
Vancouver
Gleeson D, Naveed M, Moorhead L, McAteer H, Sewell G, McGuire A, et al. Acceptability of ‘as needed’ biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae068
BibTeX
@article{Gleeson2024,
author = {Gleeson, David and Naveed, Maneeha and Moorhead, Lucy and McAteer, Helen and Sewell, Georgia and McGuire, Arlene and Weinman, John and Barker, Jonathan N W N and Norton, Sam and Chapman, Sarah C E and Smith, Catherine H and Mahil, Satveer K},
title = {Acceptability of ‘as needed’ biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljae068}
}
EUVIMED